FINWIRES · TerminalLIVE
FINWIRES

Mizuho Downgrades Apogee Therapeutics to Neutral From Outperform, Lifts Price Target to $135 From $110 Amid AbbVie Deal

By

Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $132.64, according to analysts polled by FactSet.

What else is happening in Research?